Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis

BACKGROUND/AIMS: Data on the efficacy and safety of the adalimumab biosimilar Exemptia are limited. METHODS: Patients with moderate-to-severe active steroid-refractory ulcerative colitis (UC) treated at Dayanand Medical College and Hospital, India were offered cyclosporine A, biologicals or biosimil...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Intest Res
Autori principali: Midha, Vandana, Mahajan, Ramit, Mehta, Varun, Narang, Vikram, Singh, Arshdeep, Kaur, Kirandeep, Sood, Ajit
Natura: Artigo
Lingua:Inglês
Pubblicazione: Korean Association for the Study of Intestinal Diseases 2018
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5797276/
https://ncbi.nlm.nih.gov/pubmed/29422802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2018.16.1.83
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi